Introduction
============

Mansonelliasis is one of several filarial nematode infections for which humans are the definitive host. This puts it in the same category as several parasitic infections of importance to global public health, including onchocerciasis, lymphatic filariasis, dracunculiasis, and loiasis. The three agents that cause mansonelliasis - *Mansonella perstans, M. streptocerca*, and *M. ozzardi* - vary in features such as anatomy and periodicity, the vectors that transmit the agent to humans, the clinical signs and symptoms they cause, and the world regions where they are endemic. While some of these major filarial infections have garnered international attention - onchocerciasis (river blindness) ([@R24]) and dracunculiasis (Guinea worm) ([@R9]; [@R17]) have been the focus of global eradication efforts - mansonelliasis has been neglected.

This paper is the first systematic global review of the epidemiologic literature on all three forms of mansonelliasis. A systematic search strategy was used to identify 46 original scientific articles of the prevalence of mansonelliasis. These publications report on studies from 18 countries in Africa and Latin America. After providing a brief background on the key features of each of the three types of mansonelliasis, this paper provides a comparison of the epidemiology of these infections, with an emphasis on at-risk populations and geographic regions. Up-to-date epidemiological information is essential for making differential diagnoses, planning public health interventions, and advancing research in the field.

Background on Mansonelliasis
============================

Agent and Vector Characteristics
--------------------------------

Three types of *Mansonella*, which are filarial nematodes (roundworms), are known to infect humans: *M. perstans* (formerly *Dipetalonema perstans*), *M. streptocerca* (formerly *Dipetalonema streptocerca*), and *M. ozzardi* ([@R18]; [@R23]; [@R29]). The life cycles for all three species are similar, involving development in both an insect vector and a primate host. *Culicoides* (biting midges) are effective vectors for all three species; *Simulium* (black flies) are a vector only for *M. ozzardi* ([@R49]). Both vectors require blood meals in order for their eggs to mature ([@R13]). When a female arthropod takes a blood meal from an infected host, microfilariae are ingested by the insect, penetrate the insect\'s gut and go through several maturation stages in the thoracic muscles over 6 to 12 days before migrating to the head and proboscis, where they can be transferred to a primate through an insect bite ([@R13]; [@R18]). Humans are the only known vertebrate host for *M. ozzardi*; other primates can serve as host to *M. perstans* and *M. streptocerca* ([@R23]). After the vector deposits filarial larvae onto the skin of the host, the larvae penetrate into the bite wound, mature into adult worms, and then the adult female worms produce unsheathed microfilariae that circulate in the blood (all three species) or diffuse into the skin (*M. streptocerca* only) of the primate host ([@R13]; [@R18]; [@R23]). All three species have non-periodic microfilariae that circulate in peripheral blood throughout the day and night ([@R23]; [@R40]; [@R48]). The size of the adult worms varies by species, and microfilariae differ in the shape of the tail and the distribution of body nuclei. Key differences between these species are highlighted on [Table 1](#T1){ref-type="table"}.

###### 

Agent characteristics \[CDC, 2004; [@R23]; [@R29]\].

  -------------------------------------------------------------------------------------------------------------------
  Agent             *Mansonella perstans*          *Mansonella streptocerca*        *Mansonella ozzardi*
  ----------------- ------------------------------ -------------------------------- ---------------------------------
  Adult Size        4--8 cm × 0.06 mm              2 cm × 0.01 mm                   3--5 cm × 0.07--0.15 mm

  Microfilarial\    100--200 µm × 5 µm;\           180--240 µm × 2.5--5 µm;\        170--240 µm × 3--4 µm;\
  Characteristics   blunt rounded tail; body\      curved hooked "Shepherd\'s\      long thin pointed tail; body\
                    nuclei extend to tip of tail   crook" tail; body nuclei\        nuclei do not extend to tip of\
                                                   extend to tip of tail            tail

  Vector            *Culicoides* spp.\             *Culicoides* spp.\               *Culicoides* spp.\
                    (biting midges)                (biting midges)                  (biting midges) and\
                                                                                    *Simulium* spp. (blackflies)

  Hosts             humans, gorillas, and\         humans and monkeys               humans
                    monkeys                                                         

  Signs /\          usually asymptomatic           often asymptomatic; may\         often asymptomatic; may\
  Symptoms                                         cause chronic pruritus\          cause malaise
                                                   (itchiness) and thick papules\   
                                                   on skin                          

  Common Adult\     body cavities                  subcutaneous tissues             subcutaneous tissues
  Locations                                                                         

  Common\           blood                          skin                             blood
  Microfilarial\                                                                    
  Locations                                                                         

  Diagnosis         peripheral blood smear         skin snip                        blood smear

  Recommended\      mebendazole                    DEC (diethylcarbamazine) /\      ivermectin
  Treatment                                        ivermectin                       

  Geographic\       Africa and the Americas        West and central Africa          the Americas
  Range                                                                             
  -------------------------------------------------------------------------------------------------------------------

Clinical Characteristics
------------------------

[Table 1](#T1){ref-type="table"} highlights key differences in signs and symptoms, diagnosis, and treatment between the three species. Infection with any of the three is often asymptomatic. Symptoms that do occur are related to the preferred location of the agent: *M. perstans* are typically found in body cavities, *M. streptocerca* in dermal and subcutaneous tissue, and *M. ozzardi* in subcutaneous tissues ([@R23]; [@R29]). Symptoms of infection with *M. perstans* may include pectoral and chest pains, periodic dizziness, joint and back pain, and ocular symptoms ([@R4]; [@R16]; [@R15]). Infection with *M. streptocerca*, which is found under the skin, is associated with cutaenous edema (build-up of fluid in the skin), thickening of the skin, formation of hypopigmented macules (flat blotches) and papules (raised bumps), and pruritus (itchiness) ([@R29]; [@R20]). *M. ozzardi* may cause symptoms that include skin rashes, headaches, fever, pruritus, lymphedema (swelling of the arms or legs), and joint pain ([@R18]; [@R23]).

Diagnosis and Treatment
-----------------------

Diagnosis and treatment also vary by species ([Table 1](#T1){ref-type="table"}). Blood smears that look for microfilariae are the easiest way to diagnose *M. perstans* and *M. ozzardi* ([@R18]). *M. streptocerca* microfilariae do not circulate in the blood, so it is necessary to take a skin snip ([@R18]). Care must be taken to differentiate mansonelliasis from onchocerciasis or other filarial infections ([@R20]). Treatment must be specific to the infective agent. *M. perstans* is most effectively treated with mebendazole; ivermectin is not effective against *M. perstans*, but is the drug of choice for treating *M. ozzardi* ([@R23]; [@R29]). Both diethylcarbamazine (DEC) and ivermectin have been used to treat *M. streptocerca* infection ([@R23]).

Methods
=======

Systematic reviews of the literature minimize the selection bias that may occur in narrative reviews that select articles by hand rather than by using a strict set of inclusion criteria. This methodical approach yields a valid and comparable set of research articles which together can reveal trends and gaps in the published research literature.

A systematic review of original research articles focusing on the prevalence of mansonelliasis was conducted using PubMed, a database from the U.S. National Institutes of Health that searches all MEDLINE citations along with several other databases and older publications ([Figure 1](#F1){ref-type="fig"}). A search for "mansonelliasis" yielded 173 results. The abstracts and/or full-texts of these articles were screened for eligibility. Of the 173 articles, 127 were ineligible: 30 that included only individuals with mansonelliasis and did not provide any population-based statistics, 26 that examined the vectors of infection rather than the human hosts, 22 that reported solely on laboratory techniques and diagnostic methods, 18 that evaluated treatment for mansonelliasis, 16 that focused on a disease other than mansonelliasis and only mentioned mansonelliasis in the commentary, and 15 additional articles that did not report population-based prevalence rates.

![Search strategy.](AJID0401-0007Fig1){#F1}

All of the 46 remaining articles were located and read, and information about the study country, study years, sample size, age range of participants, and prevalence was recorded. All languages were eligible for inclusion, and the 46 eligible articles were in English (39), Spanish (3), Portuguese (3), and French (1).

Results
=======

The goals of the systematic review were to identify the areas of the world where mansonelliasis has been studied, to identify the prevalence rate in affected communities, and to list the risk factors that have been identified for each species. These findings are presented below and in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, and [4](#T4){ref-type="table"}.

###### 

Epidemiological studies of *M. perstans*.

  -----------------------------------------------------------------------------------
  Country        Study Year   Sample Size   Age Range\   Prevalence       Reference
                                            (years)                       
  -------------- ------------ ------------- ------------ ---------------- -----------
  Colombia       \--          604           \--          6%               [@R32]

  Burkina Faso   2001         3303          ≥ 1          6%               [@R34]

  Cameroon       1992         466           ≥ 0.5        27%              [@R40]

  \--            1458         ≥ 15          70%          [@R57]           

  Congo          1985--1986   2313          ≥ 1          29%              [@R42]

  Gabon          1984--1985   411           9--70        49%              [@R55]

  Guinea         1989         829           ≥ 10         66%              [@R56]

  Mali           \--          40            18--65       75%              [@R31]

  Nigeria        2003--2004   373           \--          3 %              [@R3]

  1996--2000     755          ≥ 5           9%           [@R4]            

  1997--1998     373          4--55         3%           [@R1]            

  1988--1991     4183         0--70         29%          [@R5]            

  1993           840          ≥ 1           15%          [@R54]           

  1989           2552         \--           11%          [@R2]            

  1984--1987     940          3--80         8%           [@R53]           

  \--            845          \--           13%          [@R51]           

  1983--1984     1674         ≥ 1           47%          [@R7]            

  \--            1351         ≥ 1           46%          [@R52]           

  Sierra Leone   1993         630           5--70        6 %              [@R26]

  Togo           \--          182           \--          42%              [@R47]

  Uganda         2005--2006   1566          ≥ 1          65%              [@R8]

  2003--2005     2499         14--47        21%          [@R30]           

  2003           12207        5--19         61%          Onapa, 2005      

  1998           3548         \--                        [@R44]           

  1994--1995     233          ≥ 14          96%          Fischer, 1997a   

  1991--1993     1543         ≥ 14          49%          Fischer, 1996    
  -----------------------------------------------------------------------------------

\--: information not provided in article

###### 

Epidemiological studies of *M. streptocerca*.

  ----------------------------------------------------------------------------------------
  Country            Study Year   Sample Size   Age Range\   Prevalence   Reference
                                                (years)                   
  ------------------ ------------ ------------- ------------ ------------ ----------------
  Central African\   \--          267           1--100       14%          [@R43]
  Republic                                                                

  Nigeria            1990--1992   1349          0--70        0.5%         [@R6]

  Uganda             1994--1995   806           ≥ 14         61%          Fischer, 1997a
  ----------------------------------------------------------------------------------------

\--: information not provided in article

###### 

Epidemiological studies of *M. ozzardi*.

  -----------------------------------------------------------------------------
  Country      Study Year   Sample Size   Age Range\   Prevalence   Reference
                                          (years)                   
  ------------ ------------ ------------- ------------ ------------ -----------
  Bolivia      1997         594           0--85        26%          [@R10]

  Brazil       2007         129           ≥ 2          30%          [@R38]

  2006         543          \--           19%          [@R19]       

  \--          496          \--           28%          [@R25]       

  \--          386          \--           4%           [@R50]       

  \--          262          \--           27%          [@R35]       

  Colombia     \--          347           8--70        49%          [@R37]

  \--          627          \--           3%           [@R33]       

  \--          604          \--           13%          [@R32]       

  Haiti        \--          1165          all          16%          [@R46]

  Mexico       1956         329           \--          61%          [@R12]

  Trinidad     \--          4,488         ≥ 5          5%           [@R41]

  Venezuela    \--          1057          \--          10%          [@R28]

  1983--1989   423          \--           36%          [@R39]       

  \--          139          \--           58%          [@R27]       

  1977         146          ≥ 6           22%          [@R36]       

  \--          187          \--           10%          [@R11]       
  -----------------------------------------------------------------------------

\--: information not provided in article

*Mansonella perstans* is found in both Africa and the Americas, but has primarily been studied in Africa ([Table 2](#T2){ref-type="table"}). The prevalence in endemic areas varies greatly even within small geographic regions. For example, a 2003 study of school children in Uganda showed variation in school-level prevalence ranging from 0.4% to 72.8% ([@R45]), and a 2005--2006 study in Uganda found a rate of 57.7% in one community and 76.5% in a neighboring community ([@R8]). Other studies from Uganda have found village prevalence rates as low as 2% ([@R44]) and 21% ([@R30]) and as high as 96% ([@R20]). A study in Cameroon found village prevalence rates ranging from 55% to 100% ([@R57]), while another study from Cameroon found a lower prevalence rate of 26.6% ([@R40]). A study of villages in Congo found village rates ranging from 22.0% to 89.5% ([@R42]) and a study in Burkina Faso found village rates ranging from 3.5% to 14% ([@R34]). Prevalence rates from other studies in West and Central Africa demonstrate a similarly wide infection rate, ranging from 3.2% to 47% in Nigeria ([@R1]; [@R2]; [@R5], [@R4]; [@R7]; [@R52], [@R51]; [@R53]; [@R54]) and 6.0% in Sierra Leone ([@R26]) to 49.1% in Gabon ([@R55]), 66.3% in Guinea ([@R56]), and 75% in Mali ([@R31]). The only recent study from Latin America was conducted among an indigenous population in Venezuela and found a prevalence of 11.3% ([@R28]). A study from Colombia found a prevalence of 6% in affected communities in the 1980s ([@R32]).

Co-infection with *M. perstans* and other filarial infections appears to be common. 42.3% of onchocerciasis patients in a study in Togo were co-infected with *M. perstans* ([@R47]), 36.9% of participants in a study in Cameroon were infected with both *M. perstans* and *O. volvulus* ([@R57]), 14% of participants in a study in Gabon had both *M. perstans* and *L. loa* ([@R55]), 10.1% of persons with *M. perstans* infection in a study from Nigeria also had *L. loa* ([@R53]), and 9% of participants in a study conducted in the Congo were infected with both *M. perstans* and *L. loa* and 7% had both *M. perstans* and *M. streptocerca* ([@R42]). Given the concern that has been raised about filarial co-infection with other agents, this may be an area of concern ([@R14]; [@R24]).

Most studies that examined differences in *M. perstans* prevalence by sex found no difference between males and females ([@R1]; [@R8]; [@R14]; [@R26]; [@R53]; [@R54]) although several other studies observed a higher rate in males than females ([@R4]; [@R40]; [@R42]; [@R57]). Studies of the association between age and infection consistently found a higher rate in adults than children ([@R1]; [@R4]; [@R8]; [@R26]; [@R31]; [@R40]; [@R42]; [@R53]; [@R57]).

*Mansonella streptocerca* occurs in west and central Africa, and has been the focus of relatively few studies ([Table 3](#T3){ref-type="table"}). As was found for *M. perstans*, the prevalence rate appears to vary widely within endemic areas. A study in western Uganda in the mid-1990s found that the village prevalence ranged from 5% to 89% ([@R20]). A study from the 1980s conducted in the Central African Republic found a prevalence of 13.5% ([@R43]) and a study in Nigeria from the early 1990s found a prevalence of 0.5% ([@R6]). Additional studies are required to establish the geographic range where this agent is endemic and to identify risk factors.

*Mansonella ozzardi* infection, also known as mansonellosis, occurs only in the Americas ([Table 4](#T4){ref-type="table"}). In the past ten years, the results of cross-sectional studies from Brazil ([@R19]; [@R25]; [@R38]), Bolivia ([@R10]), and Venezuela ([@R28]) have been published. Most of the studies in Brazil and Venezuela were conducted in communities located along rivers in the Amazon basin and focused on indigenous groups. The prevalence rates ranged from 9.9% ([@R28]) to 18.9% ([@R19]) to 28.2 % ([@R25]) to 30.2% ([@R38]). Older studies from Brazil found prevalence rates ranging from 4% ([@R50]) to 27% ([@R35]). The Bolivian study also focused primarily on an indigenous population, and found a total prevalence of 0.7% in one town and 26% in a neighboring town of 26% ([@R10]), which suggests the same diverse range of prevalence rates found for the other species. Prevalence rates from studies of rural areas in Venezuela ranged from 11% ([@R11]) to 22% ([@R36]) to 30% ([@R22]) to 36% ([@R39]) to 58% ([@R27]). In a study from the 1970s, about 16% ([@R46]) of inhabitants surveyed from Bayeux, Haiti, were found to be infected with *Mansonella ozzardi*. In Colombia, prevalence rates ranged from 3% ([@R33]) to 13% ([@R32]) to 49% ([@R37]). These studies consistently found that risk of infection increased with age ([@R10]; [@R36]; [@R38]; [@R41]). Although one study from Trinidad in the 1970s indicated an increased risk of infection in males ([@R41]), more recent studies from Bolivia ([@R10]) and Brazil ([@R38]) found no differences in prevalence by sex. Thus, aside from age no risk factors have been firmly established.

Discussion
==========

While the three agents that cause mansonelliasis share these similarities, they are distinct infections with unique agent, clinical, and epidemiological characteristics. Although infection is usually asymptomatic, millions of people worldwide - especially those in rural areas - are at risk. This systematic review shows that mansonelliasis may be a common infection in parts of Latin American and west and central Africa, with significant variation in prevalence rates over small geographic spaces, but the review also highlights the lack of current information about the prevalence of mansonelliasis in most areas likely to at risk. Also, although the review indicates that the risk of infection increases with age and may be higher in males than females, there is a need for additional work to identify specific demographic and environmental risk factors. Updated information will be important for making differential diagnoses in endemic and epidemic areas, promoting measures to control vectors in areas with significant burden from the disease, identifying the possible risks of co-infection with multiple filariases, and addressing the concerns of at-risk populations.
